Limited cutaneous systemic sclerosis: The unfairly neglected subset

Journal of Scleroderma and Related Disorders

Volumn 1, Issue 3, 2016, Pages 241-246

  Allanore, Yannick ^a  

^a Institut Cochin   (France)

Author keywords

Lung fibrosis; Quality of life; Registries; Scleroderma; Subset; Systemic sclerosis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT;

CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; COST; EDITORIAL; FINGER ULCER; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RAYNAUD PHENOMENON; SJOEGREN SYNDROME; SKIN FIBROSIS; SKINFOLD; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

EID: 85030790100     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.5301/jsrd.5000216     Document Type: Editorial

References (23)

1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.
2. Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford). 2015;54(8): 1454-1458.
3. Johnson SR, Khanna D, Allanore Y, Matucci-Cerinic M, Furst DE. Systemic sclerosis trial design moving forward. JSRD. 2016;1(2):177-180.
4. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
5. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573-1576.
6. Galluccio F, Walker UA, Nihtyanova S, et al. Registries in systemic sclerosis: a worldwide experience. Rheumatology (Oxford). 2011;50(1):60-68.
7. Elhai M, Avouac J, Walker UA, et al; EUSTAR co-authors. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016; 75(1):163-169.
8. Moinzadeh P, Riemekasten G, Siegert E, et al; German Network for Systemic Scleroderma. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol. 2016;43(1):66-74.
9. Patterson KA, Roberts-Thomson PJ, Lester S, et al. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. Arthritis Rheum (Munch). 2015; 67(12):3234-3244.
10. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9): 2986-2994.
11. Diab S, Dostrovsky N, Hudson M, et al; Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol. 2014;41(11): 2179-2185.
12. Marangoni RG, Rocha LF, Del Rio AP, Yoshinari NH, Marques-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology (Oxford). 2013;52(8):1520-1524.
13. Delisle VC, Hudson M, Baron M, Thombs BD, and The Canadian Scleroderma Research Group A. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. Clin Exp Rheumatol. 2014;32(6)(Suppl 86):S-10-S-14.
14. Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum. 2016;46(1):115-123.
15. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum (Munch). 2014;66(6):1625-1635.
16. Ferri C, Sebastiani M, Lo Monaco A, et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients population and review of the literature. Autoimmun Rev. 2014;13(10):1026-1034.
17. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9): 708-719.
18. Avouac J, Airó P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290-2298.
19. Coghlan JG, Denton CP, Grünig E, et al; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349.
20. Lefèvre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412-2423.
21. Elhai M, Avouac J, Kahan A, Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev. 2013;12(11):1052-1057.
22. Minier T, Péntek M, Brodszky V, et al. Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford). 2010;49(10):1920-1928.
23. Bernatsky S, Hudson M, Panopalis P, et al; Canadian Scleroderma Research GroupAdditional members of the Canadian Scleroderma Research Group are shown in Appendix A. The cost of systemic sclerosis. Arthritis Rheum. 2009;61(1):119-123.